Chris Ramsborg

Chris Ramsborg joined Flagship Pioneering in 2022 as an Operating Partner, helping founders transform breakthrough science into enduring companies. He plays a key role in shaping research and development (R&D) strategies for novel therapeutic classes while driving company growth through organizational excellence, partnerships, and business development. Chris is also responsible for setting portfolio companies’ strategic and operational objectives, including intellectual property generation, commercial assessment, budgeting, as well as cross-functional CMC, research, nonclinical, and clinical efforts.

With extensive experience in bioprocessing commercialization and novel therapeutics development, Chris has held various positions in both biotechnology startups and large biopharma. His past roles include Vice President of Cell & Gene Therapy Development at Bristol Myers Squibb, Celgene Corporation, and Juno Therapeutics. Before joining and scaling Juno Therapeutics, Chris held positions of increasing responsibility in Technical Operations at Dendreon Corporation and Early Clinical Development at Merck & Co.

Chris is a serial entrepreneur and biotechnology executive with over 25 years of product commercialization experience in novel product classes. He has extensive regulatory expertise, obtaining global health authority approval for early-in-class products, including Breyanzi, Abecma, and Provenge.

Chris earned a Ph.D. from Northwestern University and a B.S. from Stanford University, where he was also a Fulbright/DAAD Scholar. He is a Fellow of the American Institute for Medical and Biological Engineering.